مقایسهٔ روش‌ها

	کارآزمایی بالینی فاز III	آزمایش بالینی تصادفی چندمرکزی
حوزه	اپیدمیولوژی	اپیدمیولوژی
خانواده	Process / pipeline	Process / pipeline
سال پیدایش	1962 (Kefauver-Harris Amendment formalised phased drug development)	1970s–1980s (widespread adoption for large-scale efficacy trials)
پدیدآور	FDA regulatory framework / ICH guidelines	Evolved from single-center RCT methodology; consolidated through landmark trials such as the MRC streptomycin trial (1948) and large cardiovascular mega-trials of the 1970s–1980s
نوع	Confirmatory randomised controlled trial	Interventional experimental design
منبع بنیادین	Friedman, L. M., Furberg, C. D., DeMets, D. L., Reboussin, D. M., & Granger, C. B. (2015). Fundamentals of Clinical Trials (5th ed.). Springer. ISBN: 978-3319185385	Friedman, L. M., Furberg, C. D., DeMets, D. L., Reboussin, D. M., & Granger, C. B. (2015). Fundamentals of Clinical Trials (5th ed.). Springer. ISBN: 978-3319185385
نام‌های دیگر	Phase 3 trial, confirmatory trial, pivotal trial, Phase III RCT	multi-site RCT, multicenter RCT, multinational randomized trial, multicenter controlled trial
مرتبط	6	6
خلاصه	A Phase III clinical trial is a large-scale, confirmatory randomised controlled trial designed to establish the efficacy and safety of an intervention in the target patient population before regulatory submission. It builds on the signal identified in Phase II, tests the intervention at its proposed dose under controlled conditions, and provides the primary evidence base for marketing authorisation or guideline adoption.	A multicenter randomized clinical trial (RCT) is an experimental study in which eligible participants are randomly assigned to intervention or control arms simultaneously across two or more clinical sites. By combining the rigor of randomization with enrollment from geographically or institutionally diverse centers, this design produces large samples and externally valid effect estimates that single-center trials rarely achieve. It is the regulatory gold standard for confirmatory efficacy and safety evaluation of new treatments.